ImetelChat

Great! Please post links to all your - or at least your most recent - blog posts. They are difficult to get to on my mobile phone.

yes. we did hear that. a classless and misleading post on pharmanot's part.

it wasnt political, hunting, it was factual. but it was also off the mark. anna is still at the company.

Is Anna still at the company? Perhaps she is having trouble getting her H1B renewed? Trump's immigration policies are affecting more than people crossing the border. A manager at my place of work is having difficulty getting his work permit. Says under the previous admin it took a few weeks, now it ...

everyone should read _sdrawkcabeman_ (https://twitter.com/_sdrawkcabeman_) on Twitter...a heartening response.

does a shelf registration need to be dealt with prior to a sale to another company?

who knows...but not going to help people with stop losses and margin calls tomorrow.

moot point...according to my broker, one cannot place anything into a 529 plan except a mutual fund. I could do the IBB, but not today.

Does anyone expect anything "new" to come out of Needham? Is it typically a place for announcements or for clarifications of past statements? To my recollection it is the later. Reason I ask is, I'm thinking of buying some more shares to put in my sons' 529 plans but not sure when. Was thinking afte...

no mention of Janssen

Doesn't Sergei work for a company Janssen or JnJ acquired?

Let's not forget that Dr.S. announced that JnJ was going to present all data of the complete imetelstat program at end of Q2 2017 to the FDA

For sure this is written in stone? All data even from Mayo? And is Friday. June 30th the absolute last day of Q2 2017...so it has to take place by then?

Anyone know if in the Mayo Study had anyone who had clinically responded to Imetelstat previously failed on Jakafi and if so, whether their response to Imetelstat had been delayed in relation to other responses? Clearly, Tefferi has an opinion but is it based on conjecture or observation?

Right! You did say Comfort...my bad.

http://onlinelibrary.wiley.com/doi/10.1002/ajh.24592/full "Currently, many other drugs are being tested for their therapeutic value in MF and the most intriguing results were recently reported with the use of imetelestat, which is a 13-mer lipid-conjugated oligonucleotide that targets the RNA templa...

" Same lukewarm conclusions" by Dr. T? About Imetelstat? or same lukewarm conclusions from the article's author? Has Dr. T. gone from "tantamount to a cure" to being lukewarm on the efficacy of Imetelstat? I know in previous communications (was it in SF last year) he was unexcited by all treatment a...

When is AST study due for release?

still a fascinating interview...probably more so now that when I initially read it. seems almost as though JnJ has been running a long game here...reuniting Gryaznov with Imetelstat and telomerase inhibitors via buying the company he is working for and then partnering with Geron and finally, licensi...

This is what William was referring to: Street_fighter Comments (93) |+ Follow |Send Message The EMA meeting yesterday had nothing to do with imetelstat. Another drug was applying for ODD for MF, where the only existing ODD designation is imetelstat. Not newsworthy. 07 Sep 2016, 04:22 PM Report Abuse...

so...please excuse my ignorance, but what is DMC and what is this trial? I couldnt find it by googling. I presume this is relevant -- was on GERN message board AND posted by Hayflick...

posted by hayflicklim 6/29/2016 dmc indicated in trial NCT0259866 update on 6/22/162. DETERMINING NEED FOR A DMC All clinical trials require safety monitoring, but not all trials require monitoring by a formal committee that may be external to the trial organizers, sponsors, and investigators. As no...